COIOSDeep risk insights through multi-disciplinary research across the globe
White and brown eggs displayed at a market
Item new Peer-reviewed Added

Sotagliflozin after worsening heart failure is modelled at $75,510 per QALY gained

A lifetime microsimulation of patients with type 2 diabetes after worsening heart failure put sotagliflozin at $75,510 per quality-adjusted life-year gained, at an assumed net cost of $434 a month.

A patient-level Markov microsimulation applied SOLOIST-WHF trial effects to patients with type 2 diabetes starting sotagliflozin around discharge for worsening heart failure. Over a lifetime horizon, from a US payer perspective, the drug added 0.39 quality-adjusted life-years at $75,510 per QALY gained. That ratio was $71,135 per QALY in preserved ejection fraction and $87,635 in reduced ejection fraction.

Why it is interesting: The ratio is lower in preserved than in reduced ejection fraction, and rests on the assumed drug price.

Source
The American Journal of Cardiology, 30 September 2026
Paper
Cost-Effectiveness of Sotagliflozin in Heart Failure Patients with Preserved and Reduced Ejection Fractions - Results from SOLOIST-WHF
Authors
Zhang Z, Kolm P, Dolman S, Alva M, Andrade K, Bhatt DL et al.
DOI
10.1016/j.amjcard.2026.09.025
Type
Peer-reviewed article
Design
Patient-level Markov microsimulation, lifetime horizon, US payer perspective, using SOLOIST-WHF trial effects
Verdict
New finding
Driver
Value in health
Driver
Heart and stroke

Other drivers in Data, models and systems